�鶹Ů��

A National Institutes of Health advisory panel on Tuesday approved the first human use of the gene-editing technology CRISPR, for a study designed to target three types of cancer and funded by tech billionaire Sean Parker's new cancer institute. The experiment, proposed by researchers at the University of Pennsylvania, would use CRISPR-Cas9 technology to modify patients' own T cells to make them more effective in attacking melanoma, multiple myeloma and sarcoma. (McGinley, 6/21)

Members of the committee were almost unanimously enthusiastic about the proposal. Dr. Michael Atkins, an oncologist at Georgetown University School of Medicine, called it “a really exciting first-in-human” study, adding that “we’ll learn a lot” from work that could “hopefully form the basis of new [cancer] therapies.” Biochemist Paula Cannon of the University of Southern California called it “innovative,” and said the Penn scientists had adequately addressed the questions she had about the safety of the procedure, including how they would tell whether CRISPR accidentally cuts the wrong genes, a problem called off-target effects. (Begley, 6/21)